These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 22871572)

  • 21. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
    Adamopoulos C; Cave DD; Papavassiliou AG
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
    Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
    Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
    Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
    Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
    Stalnecker CA; Grover KR; Edwards AC; Coleman MF; Yang R; DeLiberty JM; Papke B; Goodwin CM; Pierobon M; Petricoin EF; Gautam P; Wennerberg K; Cox AD; Der CJ; Hursting SD; Bryant KL
    Cancer Res; 2022 Feb; 82(4):586-598. PubMed ID: 34921013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
    Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
    Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.
    Wang X; Breuer J; Garbe S; Giordano F; Brossart P; Feldmann G; Bisht S
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
    Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
    Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras
    Zhao Y; Schoeps B; Yao D; Zhang Z; Schuck K; Tissen V; Jäger C; Schlitter AM; van der Kammen R; Ludwig C; D'Haese JG; Raulefs S; Maeritz N; Shen S; Zou X; Krüger A; Kleeff J; Michalski CW; Friess H; Innocenti M; Kong B
    Gastroenterology; 2021 Apr; 160(5):1755-1770.e17. PubMed ID: 33388318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ANGPTL4 accelerates KRAS
    Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
    Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.
    Althaiban A; Thyagarajan A; Sahu RP
    Mini Rev Med Chem; 2023; 23(8):953-961. PubMed ID: 36573057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
    Mohammed A; Qian L; Janakiram NB; Lightfoot S; Steele VE; Rao CV
    Int J Cancer; 2012 Oct; 131(8):1951-62. PubMed ID: 22287227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
    Rajpurohit T; Bhattacharya S
    Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.